Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $109,101.30 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 33,061 shares of Genelux stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $3.30, for a total value of $109,101.30. Following the completion of the sale, the insider now owns 1,195,731 shares of the company’s stock, valued at $3,945,912.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 29th, Aladar Szalay sold 6,403 shares of Genelux stock. The shares were sold at an average price of $3.25, for a total transaction of $20,809.75.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Stock Up 10.1 %

Shares of GNLX opened at $3.83 on Friday. Genelux Co. has a 1 year low of $3.06 and a 1 year high of $40.98. The business’s 50 day simple moving average is $5.34 and its 200-day simple moving average is $10.26.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Research analysts predict that Genelux Co. will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Amalgamated Bank grew its holdings in shares of Genelux by 250.8% in the third quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after purchasing an additional 770 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Genelux by 216.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock worth $41,000 after acquiring an additional 2,021 shares in the last quarter. Barclays PLC increased its position in shares of Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after acquiring an additional 2,835 shares during the period. New York State Common Retirement Fund increased its position in shares of Genelux by 89.5% during the third quarter. New York State Common Retirement Fund now owns 5,495 shares of the company’s stock worth $135,000 after acquiring an additional 2,595 shares during the period. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Genelux by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock valued at $87,000 after purchasing an additional 1,573 shares during the period. Institutional investors own 37.33% of the company’s stock.

Wall Street Analysts Forecast Growth

GNLX has been the subject of a number of research reports. HC Wainwright reduced their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Benchmark reiterated a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research report on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.